Cat. No JK2454441_10_G
J&K Chemical

Product Information

Product Name
Semaglutide, 98%
Brand Name
J&K
Product Number
2454441
CAS
910463-68-2
Certificate of Analysis (COA)​
COA not found

General Information

PubChem CID
56843331
IUPAC Name
18-(1R)-4-2-2-2-2-2-2-(5S)-5-(2S)-2-(2S)-2-(2S)-5-amino-2-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S)-2-(2S,3R)-2-(2S)-2-(2S,3R)-2-2-(2S)-2-2-(2S)-2-amino-3-(1H-imidazol-5-yl)propanoylamino-2-methylpropanoylamino-4-carboxybutanoylaminoacetylamino-3-hydroxybutanoylamino-3-phenylpropanoylamino-3-hydroxybutanoylamino-3-hydroxypropanoylamino-3-carboxypropanoylamino-3-methylbutanoylamino-3-hydroxypropanoylamino-3-hydroxypropanoylamino-3-(4-hydroxyphenyl)propanoylamino-4-methylpentanoylamino-4-carboxybutanoylaminoacetylamino-5-oxopentanoylaminopropanoylaminopropanoylamino-6-(2S)-1-(2S)-1-(2S,3S)-1-(2S)-1-(2S)-1-(2S)-1-(2S)-1-(2S)-5-carbamimidamido-1-2-(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-ylamino-2-oxoethylamino-1-oxopentan-2-ylamino-3-methyl-1-oxobutan-2-ylamino-4-methyl-1-oxopentan-2-ylamino-3-(1H-indol-3-yl)-1-oxopropan-2-ylamino-1-oxopropan-2-ylamino-3-methyl-1-oxopentan-2-ylamino-1-oxo-3-phenylpropan-2-ylamino-4-carboxy-1-oxobutan-2-ylamino-6-oxohexylamino-2-oxoethoxyethoxyethylamino-2-oxoethoxyethoxyethylamino-1-carboxy-4-oxobutylamino-18-oxooctadecanoic acid
InChI Key
DLSWIYLPEUIQAV-CCUURXOWSA-N
SMILES
CCC@H(C)C@@H(C(=O)NC@@H(C)C(=O)NC@@H(CC1=CNC2=CC=CC=C21)C(=O)NC@@H(CC(C)C)C(=O)NC@@H(C(C)C)C(=O)NC@@H(CCCNC(=N)N)C(=O)NCC(=O)NC@@H(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C@H(CC3=CC=CC=C3)NC(=O)C@H(CCC(=O)O)NC(=O)C@H(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC@H(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)C@H(C)NC(=O)C@H(C)NC(=O)C@H(CCC(=O)N)NC(=O)CNC(=O)C@H(CCC(=O)O)NC(=O)C@H(CC(C)C)NC(=O)C@H(CC4=CC=C(C=C4)O)NC(=O)C@H(CO)NC(=O)C@H(CO)NC(=O)C@H(C(C)C)NC(=O)C@H(CC(=O)O)NC(=O)C@H(CO)NC(=O)C@H(C@@H(C)O)NC(=O)C@H(CC5=CC=CC=C5)NC(=O)C@H(C@@H(C)O)NC(=O)CNC(=O)C@H(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C@H(CC6=CN=CN6)N

References Data Source From Pubchem

Correction: Discontinuation of oral semaglutide due to adverse effects: a database study on Japanese individuals with type 2 diabetes

Publication Name: Diabetology International
Publication Date: 2026-05-20
DOI: 10.1007/s13340-025-00868-0|10.1007/s13340-026-00893-7

Correction: Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial

Publication Name: Diabetologia
Publication Date: 2026-03-19
DOI: 10.1007/s00125-025-06593-2|10.1007/s00125-026-06711-8

Trends in the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists among ischemic stroke patients

Publication Name: Cardiovascular Diabetology – Endocrinology Reports
Publication Date: 2026-03-10
DOI: 10.1186/s40842-026-00280-w

A bibliometric analysis of systematic reviews and meta-analyses on diabetes mellitus: global research trends from scopus database (1988–2024)

Publication Name: Cardiovascular Diabetology – Endocrinology Reports
Publication Date: 2026-03-06
DOI: 10.1186/s40842-026-00272-w

Dietary restriction in aging and longevity

Publication Name: Nature Aging
Publication Date: 2026-03-06
DOI: 10.1038/s43587-026-01091-5

Semaglutide, 98%

Just added to your wishlist:
My Wishlist
You've just added this product to the cart:
Go to cart page